Search

Your search keyword '"Isern, V."' showing total 22 results
Start Over Author "Isern, V."
22 results on '"Isern, V."'

1. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

Author

Aibar, M.A., Arcelus, J.I., Ballaz, A., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Calvo, B., Cañada, G., Cañas, I., Casado, I., Culla, A., de Miguel, J., del Toro, J., Díaz-Peromingo, J.A., Falgá, C., Fernández-Capitán, C., Font, C., Font, L., Gallego, P., García-Bragado, F., Gómez, V., González, J., Grau, E., Guil, M., Guirado, L., Gutiérrez, J., Hernández, G., Hernández-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Lacruz, B., Lecumberri, R., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Madridano, O., Maestre, A., Manrique-Abos, I., Marchena, P.J., Martín-Antorán, J.M., Martín-Martos, F., Monreal, M., Morales, M.V., Morillo, R., Nauffal, D., Nieto, J.A., Nieto, S., Núñez, M.J., Odriozola, M., Otalora, S., Otero, R., Pagán, B., Pedrajas, J.M., Pérez, C., Peris, M.L., Pons, I., Porras, J.A., Ramirez, L., Riera, A., Rivas, A., Rodríguez, C., Rodríguez-Dávila, M.A., Rosa, V., Ruiz-Giménez, N., Sampériz, A., Sánchez, R., Sala, M.C., Sahuquillo, J.C., Sanz, O., Soler, S., Suárez-González, I., Suriñach, J.M., Tiberio, G., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vicente, M.P., Vidal, G., Vilella-Tomás, V., Villalta, J., Malfante, P.C., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Tomko, T., Celis, G., Salgado, E., Sánchez, G.T., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Quere, I., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Apollonio, A., Barillari, G., Bertone, A., Bilora, F., Bucherini, E., Candelero, G., Ciammaichella, M., Di Micco, P., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Prandoni, P., Rosa, M., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Serrano, J.C., Chai-Adisaksopha, Chatree, Iorio, Alfonso, Crowther, Mark A., de Miguel, Javier, Salgado, Estuardo, Zdraveska, Marija, Fernández-Capitán, Carmen, Nieto, José Antonio, Barillari, Giovanni, Bertoletti, Laurent, and Monreal, Manuel

Published
2018
Full Text
View/download PDF

2. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site

Author

Aibar, M.A., Arcelus, J.I., Ballaz, A., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Casado, I., Culla, A., de Miguel, J., del Toro, J., Díaz-Peromingo, J.A., Falgá, C., Fernández-Capitán, C., Font, C., Font, L., Gallego, P., García-Bragado, F., García-Brotons, P., Gómez, V., González, J., Grau, E., Grimón, A., Guirado, L., Gutiérrez, J., Hernández, G., Hernández-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Lacruz, B., Lecumberri, R., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Madridano, O., Marchena, P.J., Martín-Antorán, J.M., Martín-Martos, F., Monreal, M., Morales, M.V., Nauffal, D., Nieto, J.A., Nieto, S., Núñez, M.J., Otalora, S., Otero, R., Pagán, B., Pedrajas, J.M., Pérez, C., Pérez, G., Peris, M.L., Porras, J.A., Ramírez, L., Reig, O., Riera, A., Rivas, A., Rodríguez-Dávila, M.A., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Ruiz-Martínez, C., Sampériz, A., Sala, C., Sanz, O., Soler, S., Sopeña, B., Suarez, I., Suriñach, J.M., Tiberio, G., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Vela, J., Villalta, J., Malfante, P.C., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Tomko, T., Salgado, E., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Apollonio, A., Barillari, G., Candeloro, G., Ciammaichella, M., Di Micco, P., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Mastroiacovo, D., Pace, F., Pinelli, M., Prandoni, P., Rota, L., Tiraferri, E., Tufano, A., Visonà, A., Belovs, A., Skride, A., Moreira, M., Ribeiro, J.L., Sousa, M.S., Bosevski, M., Zdraveska, M., Alatri, A., Bounameaux, H., Calanca, L., Mazzolai, L., Serrano, J.C., Decousus, Hervé, Reis, Abilio, Mahé, Isabelle, Chidiac, Jean, Bertoletti, Laurent, Font, Carme, Trujillo-Santos, Javier, Peris, Marisa, Pérez Ductor, Cristina, Nieto, Santiago, Grandone, Elvira, and Monreal, Manuel

Published
2017
Full Text
View/download PDF

3. DVT Management and Outcome Trends, 2001 to 2014

Author

Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Agudo, P., Aibar, M.A., Akasbi, M., Alcalde-Manero, M., Andújar, V., Arcelus, J.I., Ballaz, A., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Cañas, I., Casado, I., de Miguel, J., del Toro, J., Díaz, S., Díaz-Peromingo, J.A., Falgá, C., Fernández-Capitán, C., Font, C., Font, L., Gallego, P., García-Bragado, F., García-Rodenas, M., Gómez, V., González, C.J., Grau, E., Guirado, L., Gutiérrez, J., Hernández, G., Hernández-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P.J., Martín, M., Martín-Antorán, J.M., Martín-Martos, F., Monreal, M., Morales, M.V., Nauffal, D., Nieto, J.A., Nieto, S., Núñez, M.J., Orbegoso, C., Otalora, S., Otero, R., Pagán, B., Pedrajas, J.M., Pérez, C., Pérez, G., Peris, M.L., Pons, I., Porras, J.A., Reig, O., Riera-Mestre, A., Rivas, A., Rodríguez, C., Rodríguez-Dávila, M.A., Rosa, V., Rosa-Murillo, A.S., Ruiz-Giménez, N., Sahuquillo, J.C., Sala, M.C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Suriñach, J.M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vidal, G., Vilar, C., Villalta, J., Xifre, B., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Tomko, T., Celis, G., Salgado, E., Sánchez, G.T., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Quere, I., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Apollonio, A., Barillari, G., Bertone, A., Bilora, F., Bucherini, E., Ciammaichella, M., De Ciantis, P., Dentali, F., Di Micco, P., Duce, R., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rosa, M., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Mafalda, A., Ribeiro, J.L., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Morillo, Raquel, Jiménez, David, Aibar, Miguel Ángel, Mastroiacovo, Daniela, Wells, Philip S., Sampériz, Ángel, Saraiva de Sousa, Marta, Muriel, Alfonso, and Yusen, Roger D.

Published
2016
Full Text
View/download PDF

5. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry

Author

Murgier, M, Darmon, M, Zeni, F, Valle, R, Del Toro, J, Llamas, P, Mazzolai, L, Villalobos, A, Monreal, M, Brenner, B, Farge-Bancel, D, Barba, R, Di Micco, P, Bertoletti, L, Tzoran, I, Reis, A, Bounameaux, H, Maly, R, Verhamme, P, Bosevski, M, Caprini, JA, Adarraga, MD, Aibar, MA, Aibar, J, Alfonso, M, Amado, C, Aranda, C, Arcelus, JI, Ballaz, A, Barron, M, Barron-Andres, B, Bascunana, J, Blanco-Molina, A, Camon, AM, Carrasco, C, Cruz, AJ, del Pozo, R, del Toro, J, Diaz-Pedroche, MC, Diaz-Peromingo, JA, Encabo, M, Falga, C, Fernandez-Capitan, C, Fidalgo, MA, Font, C, Font, L, Furest, I, Garcia, MA, Garcia-Bragado, F, Garcia-Morillo, M, Garcia-Raso, A, Gavin, O, Gomez, V, Gonzalez-Martinez, J, Grau, E, Guijarro, R, Gutierrez, J, Isern, V, Jara-Palomares, L, Jaras, MJ, Jimenez, D, Jimenez, J, Jou, I, Joya, MD, Lalueza, A, Lima, J, Lobo, JL, Lopez-Jimenez, L, Lopez-Miguel, P, Lopez-Reyes, R, Lopez-Saez, JB, Lorente, MA, Lorenzo, A, Loring, M, Lumbierres, M, Madridano, O, Marchena, PJ, Martin-Martos, F, Martin-Romero, M, Morales, MV, Nieto, JA, Nunez, A, Nunez, MJ, Olivares, MC, Otalora, S, Otero, R, Pedrajas, JM, Pellejero, G, Perez-Ductor, C, Peris, ML, Pesce, ML, Porras, JA, Riesco, D, Rivas, A, Rodriguez-Davila, MA, Rosa, V, Rubio, CM, Ruiz-Artacho, P, Sahuquillo, JC, Sala-Sainz, MC, Samperiz, A, Sanchez-Munoz-Torrero, JF, Sancho, T, Soler, S, Soto, MJ, Surinach, JM, Tolosa, C, Torres, MI, Trujillo-Santos, J, Uresandi, F, Usandizaga, E, Vela, J, Vidal, G, Gutierrez, P, Vazquez, FJ, Vilaseca, A, Vanassche, T, Vandenbriele, C, Hirmerova, J, Salgado, E, Benzidia, I, Bura-Riviere, A, Hij, A, Merah, A, Mahe, I, Moustafa, F, Braester, A, EllisM, Bilora, F, Bortoluzzi, C, Brandolin, B, Bucherini, E, Cattabiani, C, Ciammaichella, M, Dentali, F, DiMicco, P, Giorgi-Pierfranceschi, M, Grandone, E, Imbalzano, E, Maida, R, Mastroiacovo, D, Ngoc, V, Pace, F, Pallotti, G, Parisi, R, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Romualdi, R, Siniscalchi, C, Sotgiu, P, Tiraferri, E, Tonello, D, Tufano, A, Visona, A, Skride, A, Krstevski, G, Zdraveska, M, and Caprini, J

Subjects
Risk, Pulmonary embolism, Bleeding, Mortality, Biomarkers, Acute kidney injury
Abstract

Rationale: Acute kidney injury (AKI) is associated with a poor outcome. Although pulmonary embolism(PE) may promote AKI through renal congestion and/or hemodynamic instability, its frequency and influence on outcome in patients with acute PE have been poorly studied. Methods: The frequency of AKI (defined according to the "Kidney Disease: Improving Global Outcomes" definition) at baseline and its influence on the 30-day mortality was evaluated in patients with acute PE from the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry. We used multivariate analysis to assess whether the presence of AKI influenced the risk for 30-day death. Results: The study included 21,131 patients, of whom 6222 (29.5%) had AKI at baseline: 4385 patients (21%) in stage 1, 1385 (6.5%) in stage 2 and 452 (2%) in stage 3. The proportion of patients with high-risk PE in those with no AKI, AKI stage 1, AKI stage 2 or AKI stage 3 was: 2.8%, 5.3%, 8.8% and 12%, respectively (p < 0.001). After 30 days, 1236 patients (5.9%) died. Overall mortality was 4% in patients with no AKI, 8.4% in AKI stage 1, 14% in AKI stage 2 and 17% in AKI stage 3 (all p < 0.001). AKI was independently associated with an increased risk of all-cause death at 30 days (odds ratio = 1.25; 95% CI: 1.02-1.54). Conclusions: One in every 3-4 patients with acute PE had AKI at baseline. The presence of AKI independently predicted 30-day mortality. This study suggests that AKI may deserve to be evaluated as a prognostic factor in patients with acute PE. (C) 2019 Elsevier B.V. All rights reserved.

Published
2019

6. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism

Author

Mellado, M, Trujillo-Santos, J, Bikdeli, B, Jimenez, D, Nunez, MJ, Ellis, M, Marchena, PJ, Vela, JR, Clara, A, Moustafa, F, Monreal, M, Adarraga, MD, Aibar, MA, Alfonso, M, Arcelus, JI, Ballaz, A, Banos, P, Barba, R, Barron, M, Bascunana, J, Blanco-Molina, A, Camon, AM, Carrasco, C, Chasco, L, Cruz, AJ, Del, PR, Del, TJ, Diaz-Pedroche, MC, Diaz-Peromingo, JA, Encabo, M, Falga, C, Fernandez-Aracil, C, Fernandez-Capitan, C, Fidalgo, MA, Font, C, Font, L, Furest, I, Garcia, MA, Garcia-Bragado, F, Garcia-Morillo, M, Garcia-Raso, A, Garcia-Sanchez, I, Gavin, O, Gomez, C, Gomez, V, Gonzalez, J, Grau, E, Guijarro, R, Guirado, L, Gutierrez, J, Hernandez-Blasco, L, Hernando, E, Isern, V, Jara-Palomares, L, Jaras, MJ, Joya, MD, Lima, J, Llamas, P, Lobo, JL, Lopez-Jimenez, L, Lopez-Reyes, R, Lopez-Saez, JB, Lorente, MA, Lorenzo, A, Loring, M, Lumbierres, M, Madridano, O, Maestre, A, Martin, M, Martin-Martos, F, Morales, MV, Nieto, JA, Olivares, MC, Otalora, S, Otero, R, Pedrajas, JM, Pellejero, G, Perez-Ductor, C, Peris, ML, Pons, I, Porras, JA, Riera-Mestre, A, Rivas, A, Rodriguez-Davila, MA, Rodriguez-Galan, I, Rosa, V, Rubio, CM, Ruiz-Artacho, P, Sahuquillo, JC, Sala-Sainz, MC, Samperiz, A, Sanchez-Artola, B, Sanchez-Martinez, R, Sancho, T, Soler, S, Soto, MJ, Surinach, JM, Tolosa, C, Torres, MI, Uresandi, F, Usandizaga, E, Valero, B, Valle, R, Vela, J, Vidal, G, Villalobos, A, Xifre, B, Vazquez, FJ, Vilaseca, A, Vanassche, T, Vandenbriele, C, Verhamme, P, Yoo, HHB, Wells, P, Hirmerova, J, Maly, R, Salgado, E, Benzidia, I, Bertoletti, L, Bura-Riviere, A, Falvo, N, Farge-Bancel, D, Hij, A, Merah, A, Mahe, I, Quere, I, Braester, A, Brenner, B, Tzoran, I, Antonucci, G, Bilora, F, Bucherini, E, Cattabiani, C, Ciammaichella, M, Dentali, F, Di Micco, P, Doddi, M, Duce, R, Giorgi-Pierfranceschi, M, Grandone, E, Imbalzano, E, Lessiani, G, Maggi, F, Maida, R, Mastroiacovo, D, Pace, F, Pesavento, R, Poggio, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tiraferri, E, Tonello, D, Visona, A, Zalunardo, B, Gibietis, V, Skride, A, Vitola, B, Zdraveska, M, Bounameaux, H, Calanca, L, Fresa, M, and Mazzolai, L

Subjects
Male, medicine.medical_specialty, Vena Cava Filters, Inferior vena cava filter, Hemorrhage, 030204 cardiovascular system & hematology, Lower risk, Statistics, Nonparametric, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Thromboembolism, Anticoagulants, Bleeding, Mortality, Vena cava filter, Venous thromboembolism, Internal Medicine, medicine, Humans, Registries, 030212 general & internal medicine, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Mortality rate, Heparin, Middle Aged, Surgery, Clinical trial, Treatment Outcome, Propensity score matching, Emergency Medicine, Female, business, Major bleeding, medicine.drug
Abstract

The association between inferior vena cava filter (IVC) use and outcome in patients presenting with major bleeding during anticoagulation for venous thromboembolism (VTE) has not been thoroughly investigated. We used the RIETE registry to compare the 30-day outcomes (death, major re-bleeding or VTE recurrences) in VTE patients who bled during the first 3 months of therapy, regarding the insertion of an IVC filter. A propensity score matched (PSM) analysis was performed to adjust for potential confounders. From January 2001 to September 2016, 1065 VTE patients had major bleeding during the first 3 months of anticoagulation (gastrointestinal 370; intracranial 124). Of these, 122 patients (11%) received an IVC filter. Patients receiving a filter restarted anticoagulation later (median, 4 vs. 2 days) and at lower doses (95 +/- 52 IU/kg/day vs. 104 +/- 55 of low-molecular-weight heparin) than those not receiving a filter. During the first 30 days after bleeding (after excluding 246 patients who died within the first 24 h), 283 patients (27%) died, 63 (5.9%) had non-fatal re-bleeding and 19 (1.8%) had recurrent pulmonary embolism (PE). In PSM analysis, patients receiving an IVC filter (n = 122) had a lower risk for all-cause death (HR 0.49; 95% CI 0.31-0.77) or fatal bleeding (HR 0.16; 95% CI 0.07-0.49) and a similar risk for re-bleeding (HR 0.55; 95% CI 0.23-1.40) or PE recurrences (HR 1.57; 95% CI 0.38-6.36) than those not receiving a filter (n = 429). In VTE patients experiencing major bleeding during the first 3 months, use of an IVC filter was associated with reduced mortality rates. Clinical Trial Registration NCT02832245.

Published
2019

7. Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry

Author

de Miguel-Diez, J, Lopez-de-Andres, A, Jimenez-Trujillo, I, Hernandez-Barrera, V, Jimenez-Garcia, R, Lorenzo, A, Pedrajas, JM, Visona, A, Lopez-Miguel, P, Monreal, M, Adarraga, MD, Aibar, MA, Aibar, J, Alfonso, M, Amado, C, Aranda, C, Arcelus, JI, Ballaz, A, Barba, R, Barron, M, Barron-Andres, B, Bascunana, J, Blanco-Molina, A, Camon, AM, Carrasco, C, Cruz, AJ, del Toro, J, Diaz-Pedroche, MC, Diaz-Peromingo, JA, Falga, C, Fernandez-Capitan, C, Fidalgo, MA, Font, C, Font, L, Furest, I, Garcia, MA, Garcia-Bragado, F, Garcia-Morillo, M, Garcia-Ortega, A, Gavin, O, Gomez, V, Gonzalez-Martinez, J, Grau, E, Guijarro, R, Guirado, L, Gutierrez, J, Hernandez-Blasco, L, Isern, V, Jara-Palomares, L, Jaras, MJ, Jimenez, D, Jimenez, J, Jou, I, Joya, MD, Lalueza, A, Lima, J, Lobo, JL, Lopez-Jimenez, L, Lopez-Reyes, R, Lopez-Saez, JB, Lorente, MA, Loring, M, Lumbierres, M, Madridano, O, Marchena, PJ, Martin-Martos, Morales, MV, Nieto, JA, Nunez, A, Nunez, MJ, Olivares, MC, Otalora, S, Otero, R, Pellejero, G, Perez-Ductor, C, Perez-Jacoiste, A, Penis, ML, Pesce, ML, Porras, JA, Riesco, D, Rivas, A, Rodriguez-Davila, MA, Rosa, V, Rubio, CM, Ruiz-Artacho, P, Sahuquillo, JC, Sala-Sainz, MC, Samperiz, A, Sanchez-Munoz-Torrero, JF, Sancho, T, Soler, S, Soto, MJ, Surinach, JM, Tolosa, C, Torrents, A, Torres, MI, Trujillo-Santos, J, Uresandi, F, Usandizaga, E, Valle, R, Vela, J, Vidal, G, Villalobos, A, Gutierrez, P, Vazquez, FJ, Vilaseca, A, Vanasschc, T, Vandenbriele, C, Verhamme, P, Hirmerova, J, Maly, R, Salgado, E, Benzidia, I, Bertoletti, L, Bura-Riviere, A, Farge-Bancel, D, Hij, A, Merah, A, Mahe, I, Moustafa, F, Braester, A, Brenner, B, Ellis, M, Tzoran, I, Bilora, F, Bortoluzzi, C, Brandolin, B, Bucherini, E, Cattabiani, C, Ciammaichella, M, Dentali, F, Di Micco, P, Giorgi-Pierfranceschi, M, Grandone, E, Imbalzano, E, Maida, R, Mastroiacovo, D, Ngoc, V, Pace, F, Parisi, R, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Sotgiu, P, Tiraferri, E, Tufano, A, Zalunardo, B, Kalejs, R, Skride, A, Vitola, B, Bosevski, M, Zdraveska, M, Ii, B, Fresa, M, Mazzolai, L, Caprini, J, and Bui, HM

Subjects
Cardiovascular events, Type 2 diabetes mellitus, Pulmonary embolism, Comorbidity, Mortality
Abstract

Background: Among patients presenting with pulmonary embolism (PE), those with diabetes are at increased risk to die than those without diabetes. The reasons have not been identified. We used the RIETE (Registro Informatizado Enfermedad Trombo Embolica) database to compare the mortality rate and the causes of death during anticoagulation in patients with PE according to the presence or absence of diabetes. Methods: A matched retrospective cohort study from consecutively enrolled patients in RIETE, from 179 hospitals in 24 countries. For each patient with diabetes we selected two patients with no diabetes matched by age, sex and year of diagnosis of the PE. Results: As of September 2017, there were 2010 PE patients with diabetes and two age-and-gender matched controls. Mean age was 74 +/- 11 years, 46% were men. Patients with diabetes were more likely to have comorbidities, to be using antiplatelets and to have more severe PE. During anticoagulation (median, 219 days), patients with diabetes had a higher mortality (hazard ratio [HR]: 1.45; 95% confidence intervals [CI]: 1.25-1.67) and a higher rate of arterial ischemic events (HR: 2.89; 95%CI: 1.71-4.94) than those without diabetes. On multivariable analysis, diabetes was not associated with an increased risk for death (HR: 1.26; 95%CI: 0.97-1.63). We also failed to find differences according to the use of antiplatelet drugs concomitantly. Conclusions: In our cohort of patients with PE, diabetes was not an independent predictor for death. The influence of arterial events or antiplatelet drugs (if any) was low.

Published
2019

8. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis

Author

Tufano, Antonella, Ageno, Walter, Di Micco, P., Niglio, A., Rosa, V., Ballaz, A., Braester, A., Rubio, C. M., Isern, V., Imbalzano, E., Monreal, M., Adarraga, M. D., Aibar, M. A., Alfonso, M., Aranda, C., Arcelus, J. I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Braun, B., Camon, A. M., Carrasco, C., Chasco, L., Cruz, A. J., Cuevas, G., de Miguel, J., del Pozo, R., del Toro, J., Díaz-Pedroche, M. C., Díaz-Peromingo, J. A., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fernández-Muixi, J., Fidalgo, M. A., Font, C., Font, L., Furest, I., García, M. A., García-Bragado, F., García-Morillo, M., García-Raso, A., García-Rodenas, M., Gavín, O., Gómez, C., Gómez, V., González, J., Grau, E., Guijarro, R., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Jara-Palomares, L., Jaras, M. J., Jiménez, D., Jiménez, R., Joya, M. D., Lima, J., Llamas, P., Lobo, J. L., López-Jiménez, L., López-Miguel, P., López-Reyes, R., López-Sáez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Lumbierres, M., Madridano, O., Maestre, A., Marchena, P. J., Martín, M., Martín-Martos, F., Morales, M. V., Nieto, J. A., Núñez, M. J., Olivares, M. C., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Pérez-Ductor, C., Peris, M. L., Pons, I., Porras, J. A., Riera-Mestre, A., Rivas, A., Rodríguez-Dávila, M. A., Ruiz-Artacho, P., Sahuquillo, J. C., Sala-Sainz, M. C., Sampériz, A., Sánchez-Martínez, R., Sancho, T., Soler, S., Soto, M. J., Suriñach, J. M., Tolosa, C., Torres, M. I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J., Villalobos, A., Vázquez, F. J., Vilaseca, A., Vanassche, T., Vandenbriele, C., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Sánchez, G. T., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Falvo, N., Farge-Bancel, D., Hij, A., Merah, A., Mahé, I., Moustafa, F., Quere, I., Brenner, B., Ellis, M., Tzoran, I., Antonucci, G., Bilora, F., Brandolin, B., Bucherini, E., Cattabiani, C., Ciammaichella, M., Dentali, F., Duce, R., Giorgi-Pierfranceschi, M., Grandone, E., Lessiani, G., Maggi, F., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tiraferri, E., Visonà, A., Zalunardo, B., Skride, A., Bosevski, M., Zdraveska, M., Bounameaux, H., Erdmann, A., Fresa, M., Mazzolai, L., and Caprini, J.

Subjects
Male, medicine.medical_specialty, Anticoagulant therapy, Bleeding, Recurrences, Splanchnic vein thrombosis, Anticoagulants, Female, Hemorrhage, Humans, Middle Aged, Recurrence, Splanchnic Circulation, Treatment Outcome, Venous Thrombosis, Hematology, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, medicine, In patient, Prothrombin time, medicine.diagnostic_test, business.industry, Hazard ratio, Cancer, medicine.disease, Surgery, 030220 oncology & carcinogenesis, business, Venous thromboembolism, Major bleeding
Abstract

Introduction Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods We used the RIETE (Registro Informatizado Enfermedad Trombo Embolica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71–5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47–2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14–8.17) and anaemia (HR: 4.11; 95%CI: 1.45–11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68–10.1) were associated with at increased risk for major bleeding. Conclusions The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy.

Published
2017

9. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

Author

Chai-Adisaksopha, Chatree, primary, Iorio, Alfonso, additional, Crowther, Mark A., additional, de Miguel, Javier, additional, Salgado, Estuardo, additional, Zdraveska, Marija, additional, Fernández-Capitán, Carmen, additional, Nieto, José Antonio, additional, Barillari, Giovanni, additional, Bertoletti, Laurent, additional, Monreal, Manuel, additional, Aibar, M.A., additional, Arcelus, J.I., additional, Ballaz, A., additional, Barba, R., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bascuñana, J., additional, Blanco-Molina, A., additional, Bueso, T., additional, Calvo, B., additional, Cañada, G., additional, Cañas, I., additional, Casado, I., additional, Culla, A., additional, de Miguel, J., additional, del Toro, J., additional, Díaz-Peromingo, J.A., additional, Falgá, C., additional, Fernández-Capitán, C., additional, Font, C., additional, Font, L., additional, Gallego, P., additional, García-Bragado, F., additional, Gómez, V., additional, González, J., additional, Grau, E., additional, Guil, M., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández, G., additional, Hernández-Blasco, L., additional, Isern, V., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Lacruz, B., additional, Lecumberri, R., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorente, M.A., additional, Lorenzo, A., additional, Madridano, O., additional, Maestre, A., additional, Manrique-Abos, I., additional, Marchena, P.J., additional, Martín-Antorán, J.M., additional, Martín-Martos, F., additional, Monreal, M., additional, Morales, M.V., additional, Morillo, R., additional, Nauffal, D., additional, Nieto, J.A., additional, Nieto, S., additional, Núñez, M.J., additional, Odriozola, M., additional, Otalora, S., additional, Otero, R., additional, Pagán, B., additional, Pedrajas, J.M., additional, Pérez, C., additional, Peris, M.L., additional, Pons, I., additional, Porras, J.A., additional, Ramirez, L., additional, Riera, A., additional, Rivas, A., additional, Rodríguez, C., additional, Rodríguez-Dávila, M.A., additional, Rosa, V., additional, Ruiz-Giménez, N., additional, Sampériz, A., additional, Sánchez, R., additional, Sala, M.C., additional, Sahuquillo, J.C., additional, Sanz, O., additional, Soler, S., additional, Suárez-González, I., additional, Suriñach, J.M., additional, Tiberio, G., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Vela, J., additional, Vicente, M.P., additional, Vidal, G., additional, Vilella-Tomás, V., additional, Villalta, J., additional, Malfante, P.C., additional, Vanassche, T., additional, Verhamme, P., additional, Wells, P., additional, Hirmerova, J., additional, Malý, R., additional, Tomko, T., additional, Celis, G., additional, Salgado, E., additional, Sánchez, G.T., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Farge-Bancel, D., additional, Hij, A., additional, Mahé, I., additional, Merah, A., additional, Quere, I., additional, Papadakis, M., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Apollonio, A., additional, Barillari, G., additional, Bertone, A., additional, Bilora, F., additional, Bucherini, E., additional, Candelero, G., additional, Ciammaichella, M., additional, Di Micco, P., additional, Ferrazzi, P., additional, Grandone, E., additional, Lessiani, G., additional, Lodigiani, C., additional, Mastroiacovo, D., additional, Pace, F., additional, Pesavento, R., additional, Pinelli, M., additional, Prandoni, P., additional, Rosa, M., additional, Rota, L., additional, Tiraferri, E., additional, Tonello, D., additional, Tufano, A., additional, Venturelli, U., additional, Visonà, A., additional, Zalunardo, B., additional, Drucka, E., additional, Kigitovica, D., additional, Skride, A., additional, Sousa, M.S., additional, Bosevski, M., additional, Zdraveska, M., additional, Bounameaux, H., additional, Mazzolai, L., additional, and Serrano, J.C., additional

Published
2018
Full Text
View/download PDF

10. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis

Author

Universitat Rovira i Virgili, Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, Monreal M, RIETE Investigators, Universitat Rovira i Virgili, and Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, Monreal M, RIETE Investigators

Abstract

© 2018 Elsevier Ltd Introduction: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods: We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results: In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71–5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47–2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14–8.17) and anaemia (HR: 4.11; 95%CI: 1.45–11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68–10.1) were associated with at increased risk for major bleeding. Conclusions: The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy.

Published
2018

11. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

Author

Lewden, C, Bouteloup, V, De Wit, S, Sabin, C, Mocroft, A, Wasmuth, Jc, van Sighem, A, Kirk, O, Obel, N, Panos, G, Ghosn, J, Dabis, F, Mary Krause, M, Leport, C, Perez Hoyos, S, Sobrino Vegas, P, Stephan, C, Castagna, A, Antinori, A, d'Arminio Monforte, A, Torti, C, Mussini, Cristina, Isern, V, Calmy, A, Teira, R, Egger, M, Grarup, J, Chêne, G, Collaboration of Observational HIV Epidemiological Research Europe in EuroCoord, Other departments, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, Lewden, Charlotte, Bouteloup, Vincent, De Wit, Stephane, Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Group, and Castagna, A

Subjects
CD4, HIV, AIDS, mortality, Adult, Male, medicine.medical_specialty, Epidemiology, Anti-HIV Agents, Population, 610 Medicine & health, HIV Infections, Article, Europe/epidemiology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), Risk Factors, Cause of Death, medicine, Humans, 030212 general & internal medicine, Poisson Distribution, education, Cause of death, ddc:616, 0303 health sciences, education.field_of_study, 030306 microbiology, business.industry, Mortality rate, General Medicine, medicine.disease, 3. Good health, CD4 Lymphocyte Count, Europe, HIV Infections/drug therapy/mortality, Anti-HIV Agents/therapeutic use, Immunology, Cohort, Observational study, Female, business, Cohort study, Demography
Abstract

Background Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population. Methods Adults were eligible if they initiated combination anti-retroviral treatment (cART) between 1998 and 2008 and had one prior CD4 measurement within 6 months. Standardized mortality ratios (SMRs) and excess mortality rates compared with the general population were estimated using Poisson regression. Periods of follow-up were classified according to the current CD4 count. Results Of the 80 642 individuals, 70% were men, 16% were injecting drug users (IDUs), the median age was 37 years, median CD4 count 225/mm3 at cART initiation and median follow-up was 3.5 years. The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3, women: 0.9), 4.2 times as high as that in the general population (SMR for men: 3.8, for women: 7.4). Among 35 316 individuals with a CD4 count ≥500/mm3, the mortality rate was 0.37/100 PY (SMR 1.5); mortality rates were similar to those of the general population in non-IDU men [SMR 0.9, 95% confidence interval (95% CI) 0.7-1.3] and, after 3 years, in women (SMR 1.1, 95% CI 0.7-1.7). Mortality rates in IDUs remained elevated, though a trend to decrease with longer durations with high CD4 count was seen. A prior AIDS diagnosis was associated with higher mortality. Conclusions Mortality patterns in most non-IDU HIV-infected individuals with high CD4 counts on cART are similar to those in the general population. The persistent role of a prior AIDS diagnosis underlines the importance of early diagnosis of HIV infection

Published
2012
Full Text
View/download PDF

12. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site

Author

Mahé, Isabelle, primary, Chidiac, Jean, additional, Bertoletti, Laurent, additional, Font, Carme, additional, Trujillo-Santos, Javier, additional, Peris, Marisa, additional, Pérez Ductor, Cristina, additional, Nieto, Santiago, additional, Grandone, Elvira, additional, Monreal, Manuel, additional, Aibar, M.A., additional, Arcelus, J.I., additional, Ballaz, A., additional, Barba, R., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bascuñana, J., additional, Blanco-Molina, A., additional, Bueso, T., additional, Casado, I., additional, Culla, A., additional, de Miguel, J., additional, del Toro, J., additional, Díaz-Peromingo, J.A., additional, Falgá, C., additional, Fernández-Capitán, C., additional, Font, C., additional, Font, L., additional, Gallego, P., additional, García-Bragado, F., additional, García-Brotons, P., additional, Gómez, V., additional, González, J., additional, Grau, E., additional, Grimón, A., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández, G., additional, Hernández-Blasco, L., additional, Isern, V., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Lacruz, B., additional, Lecumberri, R., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorente, M.A., additional, Lorenzo, A., additional, Madridano, O., additional, Marchena, P.J., additional, Martín-Antorán, J.M., additional, Martín-Martos, F., additional, Monreal, M., additional, Morales, M.V., additional, Nauffal, D., additional, Nieto, J.A., additional, Nieto, S., additional, Núñez, M.J., additional, Otalora, S., additional, Otero, R., additional, Pagán, B., additional, Pedrajas, J.M., additional, Pérez, C., additional, Pérez, G., additional, Peris, M.L., additional, Porras, J.A., additional, Ramírez, L., additional, Reig, O., additional, Riera, A., additional, Rivas, A., additional, Rodríguez-Dávila, M.A., additional, Rosa, V., additional, Ruiz-Artacho, P., additional, Ruiz-Giménez, N., additional, Ruiz-Martínez, C., additional, Sampériz, A., additional, Sala, C., additional, Sanz, O., additional, Soler, S., additional, Sopeña, B., additional, Suarez, I., additional, Suriñach, J.M., additional, Tiberio, G., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valle, R., additional, Vela, J., additional, Villalta, J., additional, Malfante, P.C., additional, Verhamme, P., additional, Wells, P., additional, Hirmerova, J., additional, Malý, R., additional, Tomko, T., additional, Salgado, E., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Farge-Bancel, D., additional, Hij, A., additional, Mahé, I., additional, Merah, A., additional, Papadakis, M., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Apollonio, A., additional, Barillari, G., additional, Candeloro, G., additional, Ciammaichella, M., additional, Di Micco, P., additional, Ferrazzi, P., additional, Grandone, E., additional, Lessiani, G., additional, Lodigiani, C., additional, Mastroiacovo, D., additional, Pace, F., additional, Pinelli, M., additional, Prandoni, P., additional, Rota, L., additional, Tiraferri, E., additional, Tufano, A., additional, Visonà, A., additional, Belovs, A., additional, Skride, A., additional, Moreira, M., additional, Ribeiro, J.L., additional, Sousa, M.S., additional, Bosevski, M., additional, Zdraveska, M., additional, Alatri, A., additional, Bounameaux, H., additional, Calanca, L., additional, Mazzolai, L., additional, Serrano, J.C., additional, Decousus, Hervé, additional, and Reis, Abilio, additional

Published
2017
Full Text
View/download PDF

13. DVT Management and Outcome Trends, 2001 to 2014

Author

Morillo, Raquel, primary, Jiménez, David, additional, Aibar, Miguel Ángel, additional, Mastroiacovo, Daniela, additional, Wells, Philip S., additional, Sampériz, Ángel, additional, Saraiva de Sousa, Marta, additional, Muriel, Alfonso, additional, Yusen, Roger D., additional, Monreal, Manuel, additional, Decousus, Hervè, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Schellong, Sebastian, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Wells, Philip, additional, Papadakis, Manolis, additional, Agudo, P., additional, Aibar, M.A., additional, Akasbi, M., additional, Alcalde-Manero, M., additional, Andújar, V., additional, Arcelus, J.I., additional, Ballaz, A., additional, Barba, R., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bascuñana, J., additional, Blanco-Molina, A., additional, Cañas, I., additional, Casado, I., additional, de Miguel, J., additional, del Toro, J., additional, Díaz, S., additional, Díaz-Peromingo, J.A., additional, Falgá, C., additional, Fernández-Capitán, C., additional, Font, C., additional, Font, L., additional, Gallego, P., additional, García-Bragado, F., additional, García-Rodenas, M., additional, Gómez, V., additional, González, C.J., additional, Grau, E., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández, G., additional, Hernández-Blasco, L., additional, Isern, V., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorente, M.A., additional, Lorenzo, A., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín, M., additional, Martín-Antorán, J.M., additional, Martín-Martos, F., additional, Monreal, M., additional, Morales, M.V., additional, Nauffal, D., additional, Nieto, J.A., additional, Nieto, S., additional, Núñez, M.J., additional, Orbegoso, C., additional, Otalora, S., additional, Otero, R., additional, Pagán, B., additional, Pedrajas, J.M., additional, Pérez, C., additional, Pérez, G., additional, Peris, M.L., additional, Pons, I., additional, Porras, J.A., additional, Reig, O., additional, Riera-Mestre, A., additional, Rivas, A., additional, Rodríguez, C., additional, Rodríguez-Dávila, M.A., additional, Rosa, V., additional, Rosa-Murillo, A.S., additional, Ruiz-Giménez, N., additional, Sahuquillo, J.C., additional, Sala, M.C., additional, Sampériz, A., additional, Sánchez, R., additional, Sanz, O., additional, Soler, S., additional, Suriñach, J.M., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Vela, J., additional, Vidal, G., additional, Vilar, C., additional, Villalta, J., additional, Xifre, B., additional, Vanassche, T., additional, Verhamme, P., additional, Wells, P., additional, Hirmerova, J., additional, Malý, R., additional, Tomko, T., additional, Celis, G., additional, Salgado, E., additional, Sánchez, G.T., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Farge-Bancel, D., additional, Hij, A., additional, Mahé, I., additional, Merah, A., additional, Quere, I., additional, Papadakis, M., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Apollonio, A., additional, Barillari, G., additional, Bertone, A., additional, Bilora, F., additional, Bucherini, E., additional, Ciammaichella, M., additional, De Ciantis, P., additional, Dentali, F., additional, Di Micco, P., additional, Duce, R., additional, Ferrazzi, P., additional, Grandone, E., additional, Lessiani, G., additional, Lodigiani, C., additional, Mastroiacovo, D., additional, Pace, F., additional, Pesavento, R., additional, Pinelli, M., additional, Poggio, R., additional, Prandoni, P., additional, Rosa, M., additional, Rota, L., additional, Tiraferri, E., additional, Tonello, D., additional, Tufano, A., additional, Venturelli, U., additional, Visonà, A., additional, Zalunardo, B., additional, Drucka, E., additional, Kigitovica, D., additional, Skride, A., additional, Mafalda, A., additional, Ribeiro, J.L., additional, Sousa, M.S., additional, Bosevski, M., additional, Zdraveska, M., additional, Bounameaux, H., additional, and Mazzolai, L., additional

Published
2016
Full Text
View/download PDF

15. Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases.

Author

Universitat Rovira i Virgili, Lora-Tamayo J, Palom X, Sarrá J, Gasch O, Isern V, Fernández de Sevilla A, Pujol R, Universitat Rovira i Virgili, and Lora-Tamayo J, Palom X, Sarrá J, Gasch O, Isern V, Fernández de Sevilla A, Pujol R

Abstract

Hyperammonemic encephalopathy is a rarely reported complication of multiple myeloma (MM). We describe an illustrative case of hyperammonemia in the setting of an immunoglobulin (Ig) D-lambda MM, and perform a systematic review of the English-written literature. Our search yielded 26 more cases. Median age was 64 years, and 54% of patients were male. All presented with progressive impairment of their level of consciousness. Median ammonium concentration was 109 micromol/L (interquartile range, 73-149 micromol/L). Most were IgA type (10 cases), and there were 2 cases of IgD type. Most cases were aggressive or chemotherapy-resistant forms of MM. Eight patients were diagnosed with MM at the same time as the episode of hyperammonemia. Only 1 patient had signs of portal hypertension as a result of concomitant hyperdynamic heart failure. Determination of amino acid in 10 patients showed high levels of glycine, low levels of tyrosine, and a low Fischer ratio. Two patients did not receive chemotherapy and died. Twenty-two out of 25 patients who received chemotherapy against MM showed a decrease in ammonium blood concentration, and of those, 15 survived the episode (68%). Overall mortality was 44%. In conclusion, hyperammonemia is a severe complication of MM, associated with a high mortality. It should be considered in any patient with MM and a low level of consciousness. Chemotherapy directed against MM seems to be the most effective measure in order to achieve normal ammonium levels and clinical improvement.

Published
2008

18. Clinic-Based Evaluation of a Rapid Point-of-Care Test for Detection of Chlamydia trachomatisin Specimens from Sex Workers in Escuintla, Guatemala

Author

Sabido´, M., Herna´ndez, G., Gonza´lez, V., Valle`s, X., Montoliu, A., Figuerola, J., Isern, V., ado, Figueroa, L., and Casabona, J.

Abstract

ABSTRACTWe evaluated a rapid point-of-care test for the detection of Chlamydia trachomatisin specimens from 278 sex workers attending sexually transmitted infection clinics in Guatemala. The sensitivity and the specificity of the test compared to the results of PCR were 62.96% and 99.60%, respectively. The test performed moderately well as a screening tool in a context in which clinical follow-up visits are infrequent.

Published
2009
Full Text
View/download PDF

19. DVT Management and Outcome Trends, 2001 to 2014

Author

Raquel Morillo, David Jiménez, Miguel Ángel Aibar, Daniela Mastroiacovo, Philip S. Wells, Ángel Sampériz, Marta Saraiva de Sousa, Alfonso Muriel, Roger D. Yusen, Manuel Monreal, Hervè Decousus, Paolo Prandoni, Benjamin Brenner, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Henri Bounameaux, Radovan Malý, Philip Wells, Manolis Papadakis, P. Agudo, M.A. Aibar, M. Akasbi, M. Alcalde-Manero, V. Andújar, J.I. Arcelus, A. Ballaz, R. Barba, M. Barrón, B. Barrón-Andrés, J. Bascuñana, A. Blanco-Molina, I. Cañas, I. Casado, J. de Miguel, J. del Toro, S. Díaz, J.A. Díaz-Peromingo, C. Falgá, C. Fernández-Capitán, C. Font, L. Font, P. Gallego, F. García-Bragado, M. García-Rodenas, V. Gómez, C.J. González, E. Grau, L. Guirado, J. Gutiérrez, G. Hernández, L. Hernández-Blasco, V. Isern, L. Jara-Palomares, M.J. Jaras, D. Jiménez, J.L. Lobo, L. López-Jiménez, R. López-Reyes, J.B. López-Sáez, M.A. Lorente, A. Lorenzo, O. Madridano, A. Maestre, P.J. Marchena, M. Martín, J.M. Martín-Antorán, F. Martín-Martos, M. Monreal, M.V. Morales, D. Nauffal, J.A. Nieto, S. Nieto, M.J. Núñez, C. Orbegoso, S. Otalora, R. Otero, B. Pagán, J.M. Pedrajas, C. Pérez, G. Pérez, M.L. Peris, I. Pons, J.A. Porras, O. Reig, A. Riera-Mestre, A. Rivas, C. Rodríguez, M.A. Rodríguez-Dávila, V. Rosa, A.S. Rosa-Murillo, N. Ruiz-Giménez, J.C. Sahuquillo, M.C. Sala, A. Sampériz, R. Sánchez, O. Sanz, S. Soler, J.M. Suriñach, C. Tolosa, J. Trujillo-Santos, F. Uresandi, B. Valero, R. Valle, J. Vela, G. Vidal, C. Vilar, J. Villalta, B. Xifre, T. Vanassche, P. Verhamme, P. Wells, J. Hirmerova, R. Malý, T. Tomko, G. Celis, E. Salgado, G.T. Sánchez, L. Bertoletti, A. Bura-Riviere, D. Farge-Bancel, A. Hij, I. Mahé, A. Merah, I. Quere, M. Papadakis, A. Braester, B. Brenner, I. Tzoran, A. Apollonio, G. Barillari, A. Bertone, F. Bilora, E. Bucherini, M. Ciammaichella, P. De Ciantis, F. Dentali, P. Di Micco, R. Duce, P. Ferrazzi, E. Grandone, G. Lessiani, C. Lodigiani, D. Mastroiacovo, F. Pace, R. Pesavento, M. Pinelli, R. Poggio, P. Prandoni, M. Rosa, L. Rota, E. Tiraferri, D. Tonello, A. Tufano, U. Venturelli, A. Visonà, B. Zalunardo, E. Drucka, D. Kigitovica, A. Skride, A. Mafalda, J.L. Ribeiro, M.S. Sousa, M. Bosevski, M. Zdraveska, H. Bounameaux, L. Mazzolai, Morillo, R., Jimenez, D., Aibar, M. A., Mastroiacovo, D., Wells, P. S., Samperiz, A., Saraiva de Sousa, M., Muriel, A., Yusen, R. D., Monreal, M., Decousus, H., Prandoni, P., Brenner, B., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Wells, P., Papadakis, M., Agudo, P., Akasbi, M., Alcalde-Manero, M., Andujar, V., Arcelus, J. I., Ballaz, A., Barron, M., Barron-Andres, B., Bascunana, J., Blanco-Molina, A., Canas, I., Casado, I., de Miguel, J., del Toro, J., Diaz, S., Diaz-Peromingo, J. A., Falga, C., Fernandez-Capitan, C., Font, C., Font, L., Gallego, P., Garcia-Bragado, F., Garcia-Rodenas, M., Gomez, V., Gonzalez, C. J., Grau, E., Guirado, L., Gutierrez, J., Hernandez, G., Hernandez-Blasco, L., Isern, V., Jara-Palomares, L., Jaras, M. J., Lobo, J. L., Lopez-Jimenez, L., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin, M., Martin-Antoran, J. M., Martin-Martos, F., Morales, M. V., Nauffal, D., Nieto, J. A., Nieto, S., Nunez, M. J., Orbegoso, C., Otalora, S., Otero, R., Pagan, B., Pedrajas, J. M., Perez, C., Perez, G., Peris, M. L., Pons, I., Porras, J. A., Reig, O., Riera-Mestre, A., Rivas, A., Rodriguez, C., Rodriguez-Davila, M. A., Rosa, V., Rosa-Murillo, A. S., Ruiz-Gimenez, N., Sahuquillo, J. C., Sala, M. C., Sanchez, R., Sanz, O., Soler, S., Surinach, J. M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vidal, G., Vilar, C., Villalta, J., Xifre, B., Vanassche, T., Verhamme, P., Hirmerova, J., Tomko, T., Celis, G., Salgado, E., Sanchez, G. T., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahe, I., Merah, A., Quere, I., Braester, A., Apollonio, A., Barillari, G., Bertone, A., Bilora, F., Bucherini, E., Ciammaichella, M., De Ciantis, P., Dentali, F., Duce, R., Ferrazzi, P., Grandone, E., Lessiani, G., Lodigiani, C., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Rosa, M., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visona, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Mafalda, A., Ribeiro, J. L., Sousa, M. S., Zdraveska, M., and Mazzolai, L.

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Vena Cava Filters, Hemorrhage, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, Rate ratio, survival, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Cause of Death, medicine, Humans, Thrombolytic Therapy, Registries, 030212 general & internal medicine, Mortality, Population Growth, Intensive care medicine, Aged, Retrospective Studies, Aged, 80 and over, Venous Thrombosis, business.industry, Anticoagulants, Disease Management, Heparin, Low-Molecular-Weight, Length of Stay, Middle Aged, Prognosis, medicine.disease, Pulmonary embolism, Emergency medicine, Female, Cardiology and Cardiovascular Medicine, business, Venous thromboembolism, Hospital stay, DVT, prognosi
Abstract

Background A comprehensive evaluation of temporal trends in the treatment of patients who have DVT may assist with identification of modifiable factors that contribute to short-term outcomes. Methods We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies among 26,695 adults with DVT enrolled in the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2014. We also examined temporal trends in risk-adjusted rates of all-cause, pulmonary embolism-related, and bleeding-related death to 30 days after diagnosis. Results The mean length of hospital stay decreased from 9.0 days in 2001 to 2005 to 7.6 days in 2010 to 2014 (P

Published
2016

20. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis.

Author

Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, and Monreal M

Subjects
Anticoagulants pharmacology, Female, Humans, Male, Middle Aged, Recurrence, Treatment Outcome, Anticoagulants therapeutic use, Hemorrhage etiology, Splanchnic Circulation physiology, Venous Thrombosis drug therapy
Abstract

Introduction: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT., Methods: We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT., Results: In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71-5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47-2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14-8.17) and anaemia (HR: 4.11; 95%CI: 1.45-11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68-10.1) were associated with at increased risk for major bleeding., Conclusions: The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

Published
2018
Full Text
View/download PDF

21. [Panhypopituitarism and cranial nerve IV palsy: pituitary macroadenoma?].

Author

Fernández-Miró M, Isern V, Marín JH, Manresa R, and Chillarón JJ

Subjects
Adenoma blood, Adenoma pathology, Aged, 80 and over, Carotid Artery, Internal, Cavernous Sinus, Empty Sella Syndrome etiology, Female, Humans, Hydrocortisone blood, Hypopituitarism blood, Pituitary Hormones, Anterior blood, Pituitary Neoplasms blood, Pituitary Neoplasms pathology, Thyroid Hormones blood, Thyrotropin blood, Adenoma complications, Carotid Artery Diseases complications, Hypopituitarism etiology, Intracranial Aneurysm complications, Nerve Compression Syndromes etiology, Pituitary Neoplasms complications, Trochlear Nerve Diseases etiology
Published
2010
Full Text
View/download PDF

22. Sarcoidosis and autoimmune thyroid disease. A case series of ten patients.

Author

Isern V, Lora-Tamayo J, Capdevila O, Villabona C, and Mañá J

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Sarcoidosis complications, Thyroiditis, Autoimmune complications, Sarcoidosis diagnosis, Thyroiditis, Autoimmune diagnosis
Abstract

Background: Sarcoidosis coexisting with autoimmune disorders, especially with autoimmune thyroid disease (ATD), has been previously described and a common immunopathogenesis has been proposed. We report a series of ten new cases of this association from a large series of patients with sarcoidosis., Methods: The clinical records of patients diagnosed with sarcoidosis between 1984 and 2006 in the Bellvitge University Hospital were reviewed, and those who were also diagnosed as having ATD were selected. A review of the literature was performed as well., Results: Ten out of 348 (2.9%) patients with sarcoidosis were identified as having ATD. Sarcoidosis presented as Löfgren's syndrome in 8 patients. Three patients developed Graves' disease, 6 Hashimoto's thyroiditis with hypothyroidism and one had postpartum thyroiditis. In one case, ATD had developed 15 years before sarcoidosis. In the remaining nine cases, sarcoidosis preceded between 4 months to 17 years the development of ATD. In 3 of these cases, sarcoidosis was active when ATD was diagnosed. In one patient, Graves' disease developed immediately after the administration of potassium iodide to treat erythema nodosum., Conclusions: Sarcoidosis may be associated with ATD at some time of its evolution, either as hyperthyroidism or hypothyroidism. Usually, ATD does not develop during the period of activity of sarcoidosis. We suggest considering personal and family past history of thyroid disease before administering potassium iodide for erythema nodosum in patients with sarcoidosis, as it could trigger hyperthyroidism, especially in patients with iodine deficiency.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results